Catalyst Debt To Assets from 2010 to 2024
| CPRX Stock | USD 15.11 0.00 0.00% |
Debt To Assets | First Reported 2010-12-31 | Previous Quarter 0.0075375 | Current Value 0.007066 | Quarterly Volatility 0.00338421 |
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many exotic indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
Catalyst | Debt To Assets |
Latest Catalyst Pharmaceuticals' Debt To Assets Growth Pattern
Below is the plot of the Debt To Assets of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Debt To Assets | 10 Years Trend |
|
Debt To Assets |
| Timeline |
Catalyst Debt To Assets Regression Statistics
| Arithmetic Mean | 0.01 | |
| Geometric Mean | 0.01 | |
| Coefficient Of Variation | 39.92 | |
| Mean Deviation | 0 | |
| Median | 0.01 | |
| Standard Deviation | 0 | |
| Sample Variance | 0.000011 | |
| Range | 0.0175 | |
| R-Value | 0.03 | |
| Mean Square Error | 0.000012 | |
| R-Squared | 0 | |
| Significance | 0.91 | |
| Slope | 0.000024 | |
| Total Sum of Squares | 0.0002 |
Catalyst Debt To Assets History
About Catalyst Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Catalyst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Catalyst Pharmaceuticals investors use historical funamental indicators, such as Catalyst Pharmaceuticals's Debt To Assets, to determine how well the company is positioned to perform in the future. Although Catalyst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Catalyst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Catalyst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Debt To Assets | 0.01 | 0.01 |
Pair Trading with Catalyst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
| 0.66 | SBFMW | Sunshine Biopharma | PairCorr |
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.